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More than thirty years of effort have gone into the development of an HIV vaccine. Several vaccine 
candidates have been tested, including whole killed virus, expressed proteins, and recombinant virus 
vectors (a non-HIV virus expressing HIV genes). However, the most effective vaccine strategy tested 
to date, capable of complete protection in a rhesus macaque model, involves the use of a live 
attenuated virus (LAV) (Daniel et al., 1992). 
In LAV vaccines, one or more viral genes are deleted to attenuate the virus, reducing both the 
pathogenicity and the ability of the virus to replicate. However, the protection afforded by LAV 
vaccines decreases as the viral attenuation increases. Because of this correlation, LAV vaccines are 
unlikely to be used in humans, because an effective vaccine would also have a high risk of mutating 
into a pathogenic virus. Understanding how LAV vaccines confer protection could help direct vaccine 
development to more closely mimic the vaccine targets and immune response that is so effective in 
LAV vaccines. To approach this question, Dr. Paul T. Edlefsen (Vaccine and Infectious Disease 
Division), along with collaborators, used a panel of LAV vaccines to correlate their elicited immune 
responses with vaccine efficacy. 
 
Animals were vaccinated with one of five different LAVs of varying attenuation. These different 
viruses should result in varying immune responses and consequently diverse levels of protection, 
permitting statistical correlations between the immune response to each LAV and vaccine 
effectiveness.  As expected, this vaccination strategy led to a spectrum of protection, and after 
challenge, 25 out of 32 animals were at least partially protected, and 19 were completely protected 
from subsequent SIV challenge. 
Of the 11 immune parameters tested, only the magnitude of SIV-reactive CD4+ (p=0.0036) and 
CD8+ (p=0.007) T-cell responses in the lymph node statistically predicted the ability of the LAV 
vaccine to protect in this study. The authors also found that the level of LAV RNA in the lymph node 
was positively correlated with the magnitude of the T-cell response, suggesting that replicating LAV 
in the lymph node help stimulate and maintain LAV-specific T-cells in the lymph node. A microarray 
analysis found that the protected group upregulated T-cell receptor signaling genes and granzymes, 
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while the unprotected group did not, suggesting that the protected group had a higher and faster T-
cell response in the lymph node than the unprotected group. 
After the initial infection, HIV infects local white blood cells that then carry the virus through the blood 
to the lymph nodes. This study suggests that vaccination with a virus capable of replicating in these 
lymph nodes can prime and, importantly, maintain potent SIV-specific T-cells at this site. These 
activated cells may be able to intercept, control, and possibly clear virus at an early stage of 
infection. One can imagine that expressing HIV genes in a different virus backbone that also 
stimulates T-cell responses in the lymph node may provide a safe and effective alternative to a live 
attenuated HIV vaccine. 
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Schematic of various vaccine types. Whole virus may be 
inactivated by heat or chemicals, subunit vaccines may be 
generated by breaking open viruses or expressing specific 
proteins, and live attenuated viruses, the subject of this paper, 
may be generated by serial passage or mutation of specific 
genes to reduce the virus viability. 
 
